Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY)

European Urology

Volumn 63, Issue 2, 2013, Pages 254-261

  Bracarda, Sergio ^a,b   Porta, Camillo ^c   Boni, Corrado ^d   Santoro, Armando ^e   Mucciarini, Claudia ^f   Pazzola, Antonio ^g   Cortesi, Enrico ^h   Gasparro, Donatello ⁱ   Labianca, Roberto ^j   Di Costanzo, Francesco ^k   Falcone, Alfredo ^l   Cinquini, Michela ^m   Caserta, Claudia ⁿ   Paglino, Chiara ^c   De Angelis, Verena ^b  

^a Azienda USL8   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d Azienda Ospedaliera di Reggio Emilia   (Italy)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f Ospedale Ramazzini   (Italy)

^g SS Annunziata Hospital   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY HOSPITAL OF PARMA   (Italy)

^j OSPEDALI RIUNITI   (Italy)

^k Azienda Ospedaliero Universitaria di Careggi   (Italy)

^l UNIVERSITY HOSPITAL OF PISA   (Italy)

^m MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

ⁿ S MARIA HOSPITAL   (Italy)

more..

Author keywords

Antiangiogenic therapy; Interferon 2a; Renal cell carcinoma; Sorafenib

Indexed keywords

INTERFERON; SORAFENIB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOPHOSPHATEMIA; INTENTION TO TREAT ANALYSIS; KIDNEY CARCINOMA; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PIASTRINOPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84871923308     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.027     Document Type: Article

References (39)

1. S.E. Krown Interferon treatment of renal cell carcinoma: current status and future prospects Cancer 59 1987 647 651
2. H.B. Muss The role of biological response modifiers in metastatic renal cell carcinoma Semin Oncol 15 1988 30 34 (Pubitemid 19016989)
3. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell carcinoma N Engl J Med 356 2007 125 134
4. R.J. Motzer, T.E. Hutson, and P. Tonczak Sunitinib versus interferon alfa in metastatic renal cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
5. J.A. Sosman, I. Puzanof, and M.B. Atkins Opportunities and obstacles to combination targeted therapy in renal cell cancer Clin Cancer Res 13 2007 764 769
6. M.J. Ratain, T. Eisen, and W.M. Stadler Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 2505 2512 (Pubitemid 46630627)
7. R.K. Singh, M. Gutman, C.D. Bucana, R. Sanchez, N. Llansa, and I.J. Fidler Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas Proc Natl Acad Sci U S A 92 1995 4562 4566
8. J.W. Slaton, P. Perrotte, K. Inoue, C.P. Dinney, and I.J. Fidler Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on the optimization of biological dose and schedule Clin Cancer Res 5 1999 2726 2734 (Pubitemid 29493945)
9. J. Folkman, T. Browder, and J. Palmblad Angiogenesis research: guidelines for translation to clinical application Thromb Haemost 86 2001 23 33 (Pubitemid 32663933)
10. M. Eto, A. Takeuchi, T. Ohki, K. Tatsugami, and S. Naito In vitro and in vivo analysis of synergistic antitumor effects of interferon-α and sorafenib in renal cell carcinoma [abstract 16143] J Clin Oncol 26 Suppl 2008
11. B. Escudier, N. Lassau, and E. Angevin Phase I trial of sorafenib in combination with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant Clin Cancer Res 13 2007 1801 1809 (Pubitemid 46952949)
12. J.A. Gollob, W.K. Rathmell, and T.M. Richmond Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer J Clin Oncol 25 2007 3288 3295 (Pubitemid 47325614)
13. C.W. Ryan, B.H. Goldman, and P.N. Lara Sorafenib with interferon alfa-2b as first line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group J Clin Oncol 25 2007 3296 3301 (Pubitemid 47325615)
14. S.C. Chow, and M. Chang Adaptive design methods in clinical trials - a review Orphanet J Rare Dis 2 2008 11
15. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
16. E.L. Kaplan, and P. Meier Nonparametric estimation for incomplete observations J Am Stat Assoc 52 1958 457 481
17. W.D. Dupont, and W.D. Plummer Power and sample size calculations. A review and computer program Control Clin Trials 11 1990 116 128 (Pubitemid 20136185)
18. B. Escudier, C. Szczylik, and T.E. Hutson Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 7 2009 1280 1289
19. J. Folkman Seminars in medicine of the Beth-Israel Hospital, Boston. Clinical application of research on angiogenesis N Eng J Med 333 1995 1757 1763
20. B.I. Rini, and E.J. Small Biological and clinical development of vascular endothelial growth factor-targeted therapy renal cell carcinoma J Clin Oncol 23 2005 1028 1043 (Pubitemid 46202321)
21. B.I. Rini Is sorafenib plus interferon alpha 2b safe and effective in patients with renal cell carcinoma? Nat Clin Pract Urol 5 2008 132 133 (Pubitemid 351377143)
22. E. Jonasch, P. Corn, R.G. Ashe, and N.M. Tannir Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma [abstract 5104] J Clin Oncol 25 Suppl 2007
23. N.M. Tannir, A.J. Zurita, and J.V. Heymach A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: clinical results and biomarker analysis [abstract 5093] J Clin Oncol 26 Suppl 2008
24. E. Jonasch, P. Corn, and L.C. Pagliaro Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis Cancer 116 2010 57 65
25. D.R. Feldman, G.V. Kondagunta, and L. Schwartz Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma Clin Genitourin Cancer 6 2008 25 30 (Pubitemid 351656240)
26. B.I. Rini, S. Halabi, and J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
27. B. Escudier, J. Bellmunt, and S. Négrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
28. B. Melichar, S. Bracarda, and V. Matvee BEVLiN Investigators. BEVLiN: prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract 4546] J Clin Oncol 29 Suppl 2011
29. L. Albiges, S. Oudard, and S. Negrier Complete remission with tyrosine kinase inhibitors in renal cell carcinoma J Clin Oncol 30 2012 482 487
30. L. Wood Sunitinib malate for the treatment of renal cell carcinoma Expert Opin Pharmacother 13 2012 1323 1336
31. A. Flörcken, A. Takvorian, and A. Van Lessen Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma Anticancer Drugs 23 2012 298 302
32. J.H. Finke, B. Rini, and J. Ireland Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients Clin Cancer Res 14 2008 6674 6682
33. J. Ozao-Choy, G. Ma, and J. Kao The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies Cancer Res 69 2009 2514 2522
34. G.V. Kondagunta, G.R. Hudes, and R. Figlin Sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): Results of a dose-finding study [abstract 5101] J Clin Oncol 25 Suppl 2007
35. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
36. A.M. Pick, and K.K. Nystrom Pazopanib for the treatment of metastatic renal cell carcinoma Clin Ther 34 2012 511 520
37. P. Bhargava, B. Esteves, and M. Al-Adhami Activity of tivozanib (AV-951) in patients (Pts) with different histologic subtypes of renal cell carcinoma (RCC) [abstract 327] J Clin Oncol 29 Suppl 7 2011
38. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
39. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465